Epstein Secrets

and judicial inquiry into the conduct of federal prosecutors. This issue was addressed in a recent opinion by Judge Jesse Furman in United States v. Rhodes, No. 18-cr-887 (S.D.N.Y.), a prosecution for securities fraud and related offenses in the Southern District of New York. In this article, we begin

t it contemplates his criminal prosecution." Kordel, 397 U.S. at 11-12 (emphasis added). In Kordel, a corporate executive was convicted of violating the Food, Drug, and Cosmetic Act partly on the basis of earlier answers to interrogatories served on his company by the Food and Drug Administration (FDA) in a ci

and judicial inquiry into the conduct of federal prosecutors. This issue was addressed in a recent opinion by Judge Jesse Furman in United States v. Rhodes, No. 18-cr-887 (S.D.N.Y.), a prosecution for securities fraud and related offenses in the Southern District of New York. In this article, we begin

it contemplates his criminal prosecution." Kordel, 397 U.S. at 11-12 (emphasis added). In Kordel, a corporate executive was convicted of violating the Food, Drug, and Cosmetic Act partly on the basis of earlier answers to interrogatories served on his company by the Food and Drug Administration (FDA) in a ci

478, 516-17, 98 S.Ct. 2894, 2915-16, fi7 L.Ed.2d 895 (1978). Oth- er executive officials are entitled to quali- fied immunity, see, e.g.. Scheuer v. Rhodes, 416 U.S. 232, 247-49, 94 S.Ct. 1688, 1691- 92, 40 LEd.2d 90 (1974) (state executive officials), as are prosecutorial activities that are merely a

ith their access to the drug. The Supreme Court rejected the patients' claims. The Court agreed with FDA that the new drug approval provisions of the Food, Drug, and Cosmetic Act spe- cifically applied to the situation presented. (171 In one respect, however, the fact that Dr. Burzynski and his patients wer